C
CERVOMED INC.
NASDAQ: CRVO (CervoMed Inc.)
Last update: yesterday, 3:03AM9.62
0.30 (3.22%)
| Previous Close | 9.32 |
| Open | 9.41 |
| Volume | 117,597 |
| Avg. Volume (3M) | 355,655 |
| Market Cap | 89,011,168 |
| Price / Book | 2.45 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -200.58% |
| Operating Margin (TTM) | -276.55% |
| Diluted EPS (TTM) | -2.17 |
| Quarterly Revenue Growth (YOY) | -18.30% |
| Current Ratio (MRQ) | 9.78 |
| Operating Cash Flow (TTM) | -19.00 M |
| Levered Free Cash Flow (TTM) | -11.99 M |
| Return on Assets (TTM) | -56.19% |
| Return on Equity (TTM) | -93.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CervoMed Inc. | Bullish | Bearish |
AIStockmoo Score
0.6
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.38% |
| % Held by Institutions | 26.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avantax Advisory Services, Inc. | 30 Jun 2025 | 26,087 |
| Cornerstone Wealth Management, Llc | 30 Jun 2025 | 17,850 |
| Perigon Wealth Management, Llc | 30 Jun 2025 | 17,306 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (D. Boral Capital, 222.25%) | Buy |
| Median | 21.50 (123.49%) | |
| Low | 15.00 (Chardan Capital, 55.93%) | Buy |
| Average | 22.25 (131.29%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 9.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 18 Aug 2025 | 31.00 (222.25%) | Buy | 9.83 |
| 11 Aug 2025 | 15.00 (55.93%) | Buy | 9.50 | |
| Roth Capital | 12 Aug 2025 | 16.00 (66.32%) | Buy | 9.40 |
| Chardan Capital | 11 Aug 2025 | 15.00 (55.93%) | Buy | 9.50 |
| Canaccord Genuity | 29 Jul 2025 | 27.00 (180.67%) | Buy | 8.42 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |